Podcast Episodes
Episode 1: IgAN in the spotlight: Raising the profile of a rare disease
This podcast aims to share the latest advancements presented at Kidney Week 2024, with a focus on biomarkers and diagnostic tools. Listen to Professor Jonathan Barratt, Professor of Renal Medicine & Honorary Consultant Nephrologist who leads the Renal Research Group within the College of Life Sciences at the University of Leicester, UK.
The content covers the following posters:
- Csomor P, et al. Analysis of Time to Referral and Kidney Biopsy in IgA Nephropathy in Five European Countries. FR-PO877.
- Zarm AM, et al. Combination of Acanthocyturia and Elevated Serum IgA Level for the Diagnosis of IgA Nephropathy. FR-PO882.
- Zhu Q. Analysis of Clinical Risk Factors of Prognosis in IgA Nephropathy Based on Machine-Learning Approaches. FR-PO900.
- Kanzaki G, et al. Nonalbumin Protein-to-Creatinine Ratio in IgA Nephropathy: Clinical and Pathological Correlations. FR-PO885.
- Lee S, et al. Unveiling Prognostic Biomarkers in IgA Nephropathy: A Chromatin Accessibility Approach Using Peripheral Immune Cells. TH-PO542.
- Cheng H, et al. Serum GDF15 Could Predict Cardiorenal Prognosis in Patients with IgA Nephropathy. FR-PO897.
- Zhou J, et al. Urinary Proteomics Identify Biomarkers for Predicting Complete Remission of Proteinuria in Pediatric IgA Nephropathy. FR-PO903.
Episode 2: IgAN: Exploring the evolving treatment landscape
This podcast discusses the most recent evidence-based efficacy and safety data for new and emerging therapies for IgA nephropathy that were presented at Kidney Week 2024. Listen to Dr Pietro Canetta from Columbia University Medical Center in New York, USA, as he showcases the ongoing work in the field and highlights potential future treatment options.
The content covers the following posters:
- Lafayette R, et al. NeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial. FR-OR56.
- Lohana A, et al. Optimizing IgAN Treatment: Comparing Prednisone and Budesonide Efficacy and Safety. FR-OR55.
- Barratt J, et al. AFFINITY Study: 1-Year Results of Atrasentan in IgA Nephropathy. FR-PO855.
- Kooienga L, et al. PROTECT Subgroup Analysis: Clinical Benefits of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with IgAN Who Have Proteinuria above and below 1 g/g. FR-OR57.
- Ayoub I, et al. Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors in Adults with IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial. FR-PO849.
- The Anti-APRIL Antibody Sibeprenlimab Reduces Circulating Immune Complexes in Patients with IgAN: The Phase 2 ENVISION Randomized Controlled Trial, FR-OR59.
- Barratt J, et al. Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN). SA-OR102.
- Madan A, et al. Results from Longer Follow-Up with Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in IgA Nephropathy (RUBY-3 Study). FR-PO854.
- Dong L, Qin W. Efficacy and Safety of Telitacicept in IgA Nephropathy: A Real-World Study. FR-PO865.
- Tumlin JA, et al. Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial. FR-OR60.
- Barratt J, et al. A Phase 1/2 Trial of Zigakibart in IgA Nephropathy. FR-PO856.
- Barratt J, et al. Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard of Care Therapy in Individuals with Primary IgA Nephropathy: Interim Results from an Open-Label Phase 1b Study. FR-PO857.
- Lee S, et al. First-in-Class Antigen-Specific Extracellular Protein Degrader, BHV-1400 for IgA Nephropathy, Selectively Targets Galactose-Deficient IgA for Rapid and Efficient Endolysosomal Degradation in the Liver. SA-PO730.
- Cappelletto A, et al. Podocyte Gene Therapy Enables Glomerular Complement Modulation for IgAN Treatment. SA-OR63.
The Kidney Week 2024 Conference Coverage slide kit
Ask the Expert